Biofrontera Inc. reaffirmed revenue guidance for the full year 2023. The company affirms expectations for full-year 2023 growth in revenue to be at least 25% compared with 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.91 USD | -4.21% |
|
-9.00% | -67.15% |
06-24 | Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp | CI |
05-16 | Transcript : Biofrontera Inc., Q1 2024 Earnings Call, May 16, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-67.15% | 4.63M | |
+54.61% | 811B | |
+43.50% | 640B | |
-6.33% | 353B | |
+20.62% | 333B | |
+10.44% | 302B | |
+17.79% | 246B | |
+2.58% | 225B | |
+12.56% | 218B | |
+8.61% | 168B |
- Stock Market
- Equities
- BFRI Stock
- News Biofrontera Inc.
- Biofrontera Inc. Reaffirms Revenue Guidance for the Full Year 2023